Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: Apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3201-3215

  Lin, Yih Shyan ^a   Park, Jaeok ^a   De Schutter, Joris W ^a   Huang, Xian Fang ^b   Berghuis, Albert M ^a   Sebag, Michael ^b   Tsantrizos, Youla S ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GERANYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CRYSTAL STRUCTURE; DOWN REGULATION; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN PHOSPHORYLATION;

EID: 84859804837     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201657x     Document Type: Article

References (40)

1. Berndt, N.; Hamilton, A. D.; Sebti, S. M. Targeting protein prenylation for cancer theraphy Nature Rev. 2011, 11, 775-791
2. Chapman, M. A.; Lawrence, M. S.; Keats, J. J.; Cibulskis, K.; Sougnez, C.; Schinzel, A. C.; Harview, C. L.; Brunet, J. P.; Ahmann, G. J.; Adli, M.; Anderson, K. C.; Ardlie, K. G.; Auclair, D.; Baker, A.; Bergsagel, P. L.; Bernstein, B. E.; Drier, Y.; Fonseca, R.; Gabriel, S. B.; Hofmeister, C. C.; Jagannath, S.; Jakubowiak, A. J.; Krishnan, A.; Levy, J.; Liefeld, T.; Lonial, S.; Mahan, S.; Mfuko, B.; Monti, S.; Perkins, L. M.; Onofrio, R.; Pugh, T. J.; Rajkumar, S. V.; Ramos, A. H.; Siegel, D. S.; Sivachenko, A.; Stewart, A. K.; Trudel, S.; Vij, R.; Voet, D.; Winckler, W.; Zimmerman, T.; Carpten, J.; Trent, J.; Hahn, W. C.; Garraway, L. A.; Meyerson, M.; Lander, E. S.; Getz, G.; Golub, T. R. Initial genome sequencing and analysis of multiple myeloma Nature 2011, 471, 467-472
3. Rondeau, J.-M.; Bitsch, F.; Bourgier, E.; Geiser, M.; Hemmig, R.; Kroemer, M.; Lehmann, S.; Ramage, P.; Rieffel, S.; Strauss, A.; Green, J. R.; Jahnke, W. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs ChemMedChem 2006, 1, 267-273
4. Kavanagh, K. L.; Guo, K.; Dunford, J. E.; Wu, X.; Knapp, S.; Ebetino, F. H.; Rogers, M. J.; Russell, R. G. G.; Oppermann, U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7829-7834
5. Review: Dunford, J. E. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition Curr. Pharm. Des. 2010, 16, 2961-2969
6. Morgan, G. J.; Davies, F. E.; Gregory, W. M.; Cocks, K.; Bell, S. E.; Szubert, A. J.; Navarro-Coy, N.; Drayson, M. T.; Owen, R. G.; Feyler, S.; Ashcroft, A. J.; Ross, F.; Byrne, J.; Roddie, H.; Rudin, C.; Cook, G.; Jackson, G. H.; Child, J. A. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 2010, 376, 1989
7. Mönkkönen, H.; Auriola, S.; Lehenkari, P.; Kellinsalmi, M.; Hassinen, I. E.; Vepsäläinen, J.; Mönkkönen, J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates Br. J. Pharmacol. 2006, 147, 437-445
8. Mitrofan, L. M.; Pelkonen, J.; Mönkkönen, J. The level ofATP analogs and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro Bone 2009, 45, 1153-1160
9. Review: Morita, C. T.; Jin, C.; Sarikonda, G.; Wang, H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human VÎ2Vδ2 T cells: discriminating friends from foe through the recognition of prenyl pyrophosphate antigens Immunol. Rev. 2007, 215, 59-76
10. Zhang, Y.; Leon, A.; Song, Y.; Studer, D.; Haase, C.; Koscielski, L. A.; Oldfield, E. Activity of Nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines J. Med. Chem. 2006, 49, 5804-5814
11. Ezra, A.; Hoffma, A.; Breuer, E.; Alferiev, I. S.; Mönkkönen, J.; Hanany-Rozen, N.El; Weiss, G.; Stepensky, D.; Gati, I.; Cohen, H.; Törmä, S.; Amidon, G. L.; Golomb, G. A peptide prodrug approach for improving bisphosphonate oral absorption J. Med. Chem. 2000, 43, 3641-3652
12. Shmeeda, H.; Amitay, Y.; Gorin, J.; Tsemach, D.; Mak, L.; Ogorka, J.; Kumar, S.; Zhang, J. A.; Gabizon, A. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells J. Controlled Release 2010, 146, 76-83
13. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckma, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J. Pharmacol. Exp. Ther. 2001, 296, 235-242
14. Marma, M. S.; Xia, Z.; Stewart, C.; Coxon, F.; Dunford, J. E.; Baron, R.; Kashemirov, B. A.; Ebetino, F. H.; Triffitt, J. T.; Russell, G. G.; McKenna, C. E. Synthesis and biological evaluation of α-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate J. Med. Chem. 2007, 50, 5967-5975
15. Dunford, J. E.; Kwaasi, A. A.; Rogers, M. J.; Barnett, B. L.; Ebetino, F. H.; Russell, R. G. G.; Oppermann, U.; Kavanagh, K. L. Structure-activity relationship among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase J. Med. Chem. 2008, 51, 2187-2195
16. Zhang, Y.; Cao, R.; Yin, F.; Hudock, M. P.; Guo, R.-T.; Krysiak, K.; Mukherjee, S.; Gao, Y.-G.; Robinson, H.; Song, Y.; No, J. H.; Bergan, K.; Leon, A.; Cass, L.; Goddard, A.; Chang, T.-K.; Lin, F.-Y.; Van Beek, E.; Papapoulos, S.; Wang, A.H.-J.; Kubo, T.; Ochi, M.; Mukkamala, D.; Oldfield, E. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation J. Am. Chem. Soc. 2009, 131, 5153-5162
17. Wiemer, A. J.; Tong, H.; Swanson, K. M.; Hohl, R. J. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase Biochem. Biophys. Res. Commun. 2007, 353, 921-925
18. Simoni, D.; Gebbia, N.; Invidiata, F. P.; Eleopra, M.; Marchetti, P.; Rondanin, R.; Baruchello, R.; Provera, S.; Marchioro, C.; Tolomeo, M.; Marinelli, L.; Limongelli, V.; Novellino, E.; Kwaasi, A.; Dunford, J.; Buccheri, S.; Caccamo, N.; Dieli, F. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a Îδ-T lymphocyte-mediated activation mechanism J. Med. Chem. 2008, 51, 6800-6807
19. Zhang, Y.; Cao, R.; Yin, F.; Lin, F.-Y.; Wang, H.; Krysiak, K.; No, J.-H.; Mukkamala, D.; Houlihan, K.; Li, J.; Morita, C. T.; Oldfield, E. Lipophilic pyridinium bisphosphonates: potent Îδ T cell stimulators Angrew. Chem. Int. Ed. 2010, 49, 1136-1138
20. Lolli, M. L.; Rolando, B.; Tosco, P.; Chaurasia, S.; Di Stilo, A.; Lazzarato, L.; Gorassini, E.; Ferracini, R.; Oliaro-Bosso, S.; Fruttero, R.; Gasco, A. Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) Bioorg. Med. Chem. 2010, 18, 2428-2438
21. Wasko, B. M.; Smits, J. P.; Shull, L. W.; Wiemer, D. F.; Hohl, R. J. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro J. Lipid. Res. 2011, 52, 1957-1964
22. Jahnke, W.; Rondeau, J.-M.; Cotesta, S.; Marzinzik, A.; Pellé, X.; Geiser, M.; Strauss, A.; Götte, M.; Bitsch, F.; Hemmig, R.; Henry, C.; Lehmann, S.; Glickman, J. F.; Roddy, T. P.; Stout, S. J.; Green, J. R. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery Nature Chem. Biol 2010, 6, 660-666
23. De Schutter, J. W.; Zaretsky, S.; Welbourn, S.; Pause, A.; Tsantrizos, Y. S. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase Biorg. Med. Chem. Lett. 2010, 20, 5781-5786
24. Guram, A. S.; Wang, X.; Bunel, E. E.; Faul, M. M.; Larsen, R. D.; Martinelli, M. J. New catalysts for Suzuki-Miyaura coupling reactions of heteroatom-substituted heteroaryl chlorides J. Org. Chem. 2007, 72, 5104-5112
25. Fleckenstein, C. A.; Plenio, H. Highly efficient Suzuki-Miyaura coupling of heterocyclic substrates through rational reaction design Chem.-Eur. J. 2008, 14, 4267-4279
26. Matczak-Jon, E.; Ślepokura, K.; Kafarski, P. Solid state and solution behaviour of N -(2-pyridyl)- and N -(4-methyl-2-pyridyl)aminomethane-1, 1-diphosphonic acids J. Mol. Struct. 2006, 782, 81-93
27. Tarshis, L. C.; Proteau, P. J.; Kellogg, B. A.; Sacchettini, J. C.; Poulter, C. D. Regulation of product chain length by isoprenyl diphosphate synthase Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 15018-15023
28. Martin, M. B.; Arnold, W.; Heath, H. T., III; Urbina, J. A.; Oldfield, E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis Biochem. Biophys. Res. Commun. 1999, 263, 754-758
29. Räikkönen, J.; Taskinen, M.; Dunford, J. E.; Mönkkönen, H.; Auriola, S.; Mönkkönen, J. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonate in cultured cells Biochem. Biophys. Res. Commun. 2011, 407, 663-667
30. Song, L.; Poulter, C. D. Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3044-3048
31. Kavanagh, K. L.; Dunford, J. E.; Bunkoczi, G.; Russell, R. G. G.; Oppermann, U. The Crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding J. Biol. Chem. 2006, 281, 22004-22012
32. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: €‰ a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47, 1750-1759
33. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knol, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: €‰ a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
34. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision Glide: A docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196
35. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation mode. In Methods in Enzymology; Carter, C. W., Jr.; Sweet, R. M., Eds.; Elsevier: New York, 1997; Vol. 276, Macromolecular Crystallography, Part A, pp 307-326.
36. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
37. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D 2004, 60, 2126-2132
38. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Mriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. A comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D 2010, 66, 213-221
39. Vagin, A. A.; Steiner, R. S.; Lebedev, A. A.; Potterton, L.; McNicholas, S.; Long, F.; Murshudov, G. N. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use Acta Crystallogr., Sect. D 2004, 60, 2284-2295
40. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074